SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) today is providing an update on its preclinical testing program for SILENOR™ (doxepin HCl), its lead product candidate that has completed a successful Phase 3 clinical program for the treatment of insomnia. The company is confirming that it expects to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for SILENOR™ in the third quarter of 2007.
